MedElevator
Войти в исследования Journal of the American Society of Nephrology : JASN · 2025
Differential Effect of Hospitalization on Cystatin C- and Creatinine-Based Estimated GFR.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McCoy Ian E, Go Alan S, Hsu Jesse Y, Zhang Xiaoming, Muiru Anthony N, Shah Vallabh O, Weir Matthew, Rincon-Choles Hernan, Cohen Debbie L, Anderson Amanda, Jaar Bernard, Sondheimer James, Rao Panduranga S, Srivastava Anand, Dember Laura M, He Jiang, Chen Jing, Hsu Chi-Yuan, on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Investigators
Аннотация
KEY POINTS: Critical illness is known to acutely decrease eGFRdiff (estimation of GFR by cystatin C−estimation of GFR from serum creatinine [eGFRCr]), presumably because of loss of muscle mass falsely elevating eGFRCr. It is unknown whether this eGFRdiff effect occurs in all-cause hospitalizations and whether the effect persists after hospitalization. More hospitalization was associated with larger decreases in estimation of GFR by cystatin C compared with eGFRCr on measurements months after hospital discharge.
BACKGROUND: Cystatin C has entered mainstream clinical care as a measure of kidney function, joining serum creatinine, which has been used for almost a century. However, many physicians notice that estimation of GFR from serum creatinine (eGFRCr) and estimation of GFR by cystatin C (eGFRCys) values can differ considerably. Hospitalization with critical illness is known to acutely decrease eGFRdiff (eGFRCys−eGFRCr). However, whether this effect occurs in all-cause hospitalizations and persists after hospitalization is unknown.
METHODS: Among 5599 adult participants in the Chronic Renal Insufficiency Cohort study with serum creatinine and cystatin C measurements, we estimated the association of six categories of total days of hospitalization between annual study visits (never hospitalized, hospitalized <7, 7 to <14, 14 to <28, 28 to <42, and ≥42 days) and changes in eGFRCr, eGFRCys, and eGFRdiff between those study visits.
RESULTS: Compared with no hospitalization between study visits, increasing days of hospitalization were associated with decreases in eGFRCys (e.g., −3.30 [95% confidence interval, −5.48 to −1.13] ml/min per 1.73 m2 for ≥42 days of hospitalization, test for trend P < 0.001), while eGFRCr remained relatively stable (e.g., −1.12 [−2.77 to 0.53] ml/min per 1.73 m2 for ≥42 days of hospitalization, test for trend P = 0.21). The differential effect resulted in eGFRdiff becoming progressively more negative with more total days of hospitalization (test for trend P < 0.001).
CONCLUSIONS: Prolonged or repeated hospitalization was associated with larger decreases in eGFRCys compared with eGFRCr on measurements months after hospital discharge.
BACKGROUND: Cystatin C has entered mainstream clinical care as a measure of kidney function, joining serum creatinine, which has been used for almost a century. However, many physicians notice that estimation of GFR from serum creatinine (eGFRCr) and estimation of GFR by cystatin C (eGFRCys) values can differ considerably. Hospitalization with critical illness is known to acutely decrease eGFRdiff (eGFRCys−eGFRCr). However, whether this effect occurs in all-cause hospitalizations and persists after hospitalization is unknown.
METHODS: Among 5599 adult participants in the Chronic Renal Insufficiency Cohort study with serum creatinine and cystatin C measurements, we estimated the association of six categories of total days of hospitalization between annual study visits (never hospitalized, hospitalized <7, 7 to <14, 14 to <28, 28 to <42, and ≥42 days) and changes in eGFRCr, eGFRCys, and eGFRdiff between those study visits.
RESULTS: Compared with no hospitalization between study visits, increasing days of hospitalization were associated with decreases in eGFRCys (e.g., −3.30 [95% confidence interval, −5.48 to −1.13] ml/min per 1.73 m2 for ≥42 days of hospitalization, test for trend P < 0.001), while eGFRCr remained relatively stable (e.g., −1.12 [−2.77 to 0.53] ml/min per 1.73 m2 for ≥42 days of hospitalization, test for trend P = 0.21). The differential effect resulted in eGFRdiff becoming progressively more negative with more total days of hospitalization (test for trend P < 0.001).
CONCLUSIONS: Prolonged or repeated hospitalization was associated with larger decreases in eGFRCys compared with eGFRCr on measurements months after hospital discharge.